Corcept Therapeutics Incorporated (CORT)

Gross profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Gross profit (ttm)	US$ in thousands	664,158	618,752	561,029	515,898	475,893	443,941	422,374	408,303	396,473	392,365	386,832	374,966	360,697	347,710	337,965	335,092	348,292	350,270	345,213	328,762
Revenue (ttm)	US$ in thousands	675,040	628,555	569,610	523,529	482,375	450,026	428,153	413,824	401,858	397,624	392,027	380,229	365,978	352,891	343,087	340,064	353,874	356,034	351,212	334,904
Gross profit margin		98.39%	98.44%	98.49%	98.54%	98.66%	98.65%	98.65%	98.67%	98.66%	98.68%	98.67%	98.62%	98.56%	98.53%	98.51%	98.54%	98.42%	98.38%	98.29%	98.17%

December 31, 2024 calculation

Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $664,158K ÷ $675,040K
= 98.39%

Corcept Therapeutics Incorporated has consistently maintained a high gross profit margin over the years, with the margin ranging from 98.17% to 98.68% between March 31, 2020, and December 31, 2024. The trend shows a slight increase in the margin from 98.17% in March 2020 to 98.68% in September 30, 2022, followed by a gradual decrease to 98.39% by December 31, 2024.

This high and relatively stable gross profit margin indicates that the company is effectively controlling its production costs and maximizing its profitability on sales. It suggests that Corcept Therapeutics is efficient in managing its direct expenses related to the production of goods or services, resulting in a significant portion of revenues translating into gross profits.

Overall, the consistent high gross profit margin of Corcept Therapeutics reflects positively on the company's operational efficiency and ability to generate profits from its core business activities.